Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Endocrinology and Metabolism›Condition·Updated Jun 27, 2026·v1

Hypoglycemia

Hypoglycemia is a metabolic emergency defined by Whipple's triad and classified into three ADA levels (1-3). Over 95% of cases are iatrogenic in diabetes, but rare etiologies (insulinoma, CHI, autoimmune syndromes) require systematic evaluation with paired hormone testing, dynamic fasting studies, and localization. Acute management follows the Rule of 15 or parenteral glucagon/dextrose; octreotide is used for sulfonylurea overdose. Long-term prevention relies on identifying the underlying cause, using CGM and AID systems, setting individualized glycemic targets (avoiding intensive targets in critically ill patients per NICE-SUGAR), and providing structured education.

High Evidence252 references·10,806 words·44 min read·v1
hypoglycemiaendocrinologymetabolisminsulinomadiabetescongenital hyperinsulinismglucose management

Quick Reference

RxDrug of choiceFor acute severe hypoglycemia: Glucagon 1 mg IM/SC/IV (0.5 mg for children <25 kg). For sulfonylurea overdose: Octreotide 50-100 mcg SC/IV q6-12h.
AltAlternativesIV dextrose 50% (D50) 25 g (50 mL) in adults or D25 2 mL/kg in children. For insulinoma: Diazoxide 3-8 mg/kg/day PO (max 400 mg/day). For post-bariatric hypoglycemia: Acarbose 50-100 mg with meals; Avexitide 30 mg SC BID.
⊘AvoidSulfonylureas in hyperinsulinemic hypoglycemia. Non-dihydropyridine CCBs (diltiazem, verapamil) in heart failure. Intensive glycemic targets (80-110 mg/dL) in critically ill patients (NICE-SUGAR: increased mortality).
DxTest of choiceSupervised 72-hour fast (sensitivity ~95% for insulinoma). At termination: paired insulin, C-peptide, proinsulin, beta-hydroxybutyrate, and sulfonylurea screen.
ScKey scoreHypoglycemia Risk Score (age, renal function, insulin use, prior severe hypoglycemia; C-statistic 0.72 in type 2 diabetes). CGM-derived TBR2 (<54 mg/dL) >5% predicts 3-fold increased risk of Level 3 hypoglycemia.
→When to referConfirmed/suspected insulinoma, congenital hyperinsulinism, refractory post-bariatric hypoglycemia, insulin autoimmune syndrome, Type B insulin resistance, non-islet cell tumor hypoglycemia, recurrent severe hypoglycemia of uncertain etiology.
Hypoglycemia is a common, preventable emergency. Acute management follows the Rule of 15 or glucagon; long-term prevention requires identifying the etiology, using technology (CGM, AID), setting individualized glycemic targets, and providing structured education.
Hypoglycemia is a metabolic emergency defined by Whipple's triad: symptoms of low plasma glucose, a measured low glucose, and resolution of symptoms with glucose administration. The ADA classifies hypoglycemia into three levels: Level 1 (alert value ≤70 mg/dL), Level 2 (clinically significant <54 mg/dL), and Level 3 (severe, requiring assistance). Over 95% of clinically significant hypoglycemia is iatrogenic in diabetes, but rare causes like insulinoma, congenital hyperinsulinism, and autoimmune syndromes require a systematic diagnostic approach. Acute management follows the Rule of 15 for mild cases and parenteral glucagon or dextrose for severe episodes, with octreotide reserved for sulfonylurea overdose.

Overview and Recommendations

Background

  • •Hypoglycemia affects up to 10% of hospitalized patients and is the most common metabolic emergency in diabetes, with severe episodes carrying a 2-fold increased risk of cardiovascular events and a 3-fold increase in mortality in type 2 diabetes. The American Diabetes Association (ADA) classifies hypoglycemia into three levels: Level 1 (alert value ≤70 mg/dL or 3.9 mmol/L), Level 2 (clinically significant <54 mg/dL or 3.0 mmol/L), and Level 3 (severe, requiring external assistance regardless of glucose level). This tiered system replaced older symptom-based definitions and now anchors clinical decision-making, trial endpoints, and reimbursement criteria.
  • •More than 95% of clinically significant hypoglycemia is iatrogenic in patients with diabetes, driven by insulin or sulfonylurea therapy. In type 1 diabetes, severe hypoglycemia rates are approximately 100-130 episodes per 100 patient-years, while in insulin-treated type 2 diabetes the rate is 10-30 per 100 patient-years. Among non-diabetic populations, insulinoma is the most common endogenous cause of hyperinsulinemic hypoglycemia, with an incidence of 1-4 per million person-years, and is malignant in 5-10% of cases. Congenital hyperinsulinism (CHI) affects 1 in 25,000-50,000 live births, with mutations in ABCC8 and KCNJ11 accounting for the majority.
  • •The counter-regulatory axis, insulin, glucagon, epinephrine, cortisol, and growth hormone, normally maintains plasma glucose within a narrow range. Maladaptive failure of this axis underlies all hypoglycemia: excess insulin or insulin-like activity (e.g., insulinoma, sulfonylurea overdose, non-islet cell tumor hypoglycemia), deficient counter-regulation (e.g., adrenal insufficiency, growth hormone deficiency, long-standing type 1 diabetes with loss of glucagon response), and altered substrate availability (e.g., liver failure, renal failure, inborn errors of metabolism, alcohol ingestion). The biochemical signature, measured by paired insulin, C-peptide, proinsulin, and beta-hydroxybutyrate, fingerprints the specific lesion.
  • •Post-bariatric hypoglycemia (PBH), most common after Roux-en-Y gastric bypass, affects an estimated 10-30% of patients and results from rapid nutrient delivery causing exaggerated GLP-1 secretion and reactive hyperinsulinemia 1-3 hours after meals. Insulin autoimmune syndrome (Hirata disease), mediated by anti-insulin antibodies, is more common in Asian populations and often triggered by sulfhydryl-group medications. Type B insulin resistance syndrome, caused by autoantibodies to the insulin receptor, paradoxically presents with severe hypoglycemia in a subset of patients. Recognizing these syndromic contexts is essential for targeted therapy.
  • •The landmark NICE-SUGAR trial (2009) demonstrated that intensive glucose control (target 81-108 mg/dL) in critically ill patients increased mortality compared with a liberal target (<180 mg/dL) (HR 1.14, 95% CI 1.02-1.28), establishing that hypoglycemia prevention is as important as hyperglycemia management. Similarly, the ACCORD trial (2008) showed that intensive HbA1c lowering to <6.0% in type 2 diabetes increased all-cause mortality (HR 1.22, 95% CI 1.01-1.46), driven in part by severe hypoglycemia. These trials reshaped glycemic targets worldwide, emphasizing individualized goals and the need for safer therapeutic strategies.

Evaluation

  • •Suspect hypoglycemia in any patient with altered mental status, diaphoresis, palpitations, tremor, or unexplained weakness, especially those with diabetes on insulin or sulfonylureas, or in the setting of critical illness, renal failure, or alcohol use. Classic Whipple's triad (symptoms + low glucose + relief with glucose) is the diagnostic gatekeeper; without it, further workup is not indicated.
  • •Ask about timing and context: fasting versus postprandial symptoms, relation to meals or exercise, missed meals, alcohol ingestion, and any recent changes in medication doses or timing. In patients with diabetes, review the insulin or sulfonylurea regimen in detail, including type, dose, timing, and injection technique. For nocturnal hypoglycemia, ask about night sweats, morning headache, or confusional arousals.
  • •Examine for autonomic signs (tachycardia, hypertension, diaphoresis, piloerection) and neuroglycopenic signs (confusion, slurred speech, ataxia, focal neurological deficits mimicking stroke, seizures, or coma). Perform a full neurological exam: mental status, cranial nerves (pupils, extraocular movements, speech), motor strength, sensation, reflexes (hyperreflexia, Babinski sign), and coordination. Check for acanthosis nigricans (suggesting type B insulin resistance syndrome) and hepatomegaly (glycogen storage disease or lymphoma).
  • •Obtain a bedside capillary glucose immediately using a point-of-care glucometer. If glucose <70 mg/dL (3.9 mmol/L), confirm with a venous or arterial sample for accurate diagnosis; note that capillary glucose may lag in shock or peripheral edema. In any patient with altered mental status or focal neurological deficits, especially in the emergency department, check a bedside glucose before imaging; hypoglycemia can mimic acute stroke.
  • •At the time of documented hypoglycemia (glucose <54 mg/dL [3.0 mmol/L]), draw a critical sample: plasma glucose, insulin, C-peptide, proinsulin, beta-hydroxybutyrate (BOHB), and a screen for sulfonylureas and meglitinides. This paired-hormone analysis is the cornerstone of etiologic diagnosis. Suppressed BOHB (<2.7 mmol/L) indicates insulin-mediated hypoglycemia; elevated BOHB points to counter-regulatory failure or substrate deficiency.
  • •A insulin ≥3 μIU/mL (18 pmol/L) with C-peptide ≥0.6 ng/mL (0.2 nmol/L) and proinsulin ≥5 pmol/L defines endogenous hyperinsulinism (e.g., insulinoma, sulfonylurea overdose, insulin autoimmune syndrome). If C-peptide is low (<0.6 ng/mL) in the setting of high insulin, suspect exogenous insulin administration (factitious use). A negative sulfonylurea screen on a contemporaneous sample is essential to rule out surreptitious use.
  • •If spontaneous hypoglycemia is not captured and fasting hypoglycemia is suspected, perform a supervised 72-hour fast in a controlled inpatient setting. Measure plasma glucose every 4-6 hours; when glucose falls below 60 mg/dL (3.3 mmol/L), measure hourly. Terminate the fast when: glucose <45 mg/dL (2.5 mmol/L) with symptoms, glucose <50 mg/dL (2.8 mmol/L) without symptoms after 72 hours, or neuroglycopenic symptoms develop. At termination, draw the critical sample. The 72-hour fast has a sensitivity of approximately 95% for insulinoma.
  • •For patients with postprandial symptoms (occurring 2-4 hours after meals), perform a 5-hour mixed-meal test (not an oral glucose tolerance test, which can provoke dumping syndrome). The patient consumes a standardized mixed meal; glucose, insulin, and C-peptide are measured every 30 minutes. A positive test requires reproduction of symptoms with a glucose <55 mg/dL (3.0 mmol/L) and concomitant elevated insulin/C-peptide. This pattern is characteristic of post-bariatric hypoglycemia and early type 2 diabetes.
  • •Once biochemical confirmation of endogenous hyperinsulinism is established, localize the insulinoma. First-line imaging: contrast-enhanced triple-phase CT (pancreatic protocol) or endoscopic ultrasound (EUS) with fine-needle aspiration, CT sensitivity 70-80%, EUS sensitivity 80-90%. If negative, proceed to GLP-1 receptor PET/CT (68Ga-exendin-4 or 18F-exendin-4), which detects 95% of insulinomas. For occult tumors, selective arterial calcium stimulation with hepatic venous sampling (SACST) remains the gold standard: a >2-fold rise in hepatic vein insulin after calcium injection localizes the tumor to the corresponding pancreatic region.
  • •In children with congenital hyperinsulinism, obtain 18F-DOPA PET/CT to distinguish focal from diffuse disease; this determines surgical approach (focal = localized resection with high cure rate; diffuse = may require near-total pancreatectomy). Genetic testing for ABCC8, KCNJ11, GCK, GLUD1, HNF4A, and HADH is indicated in all infants with persistent hyperinsulinemic hypoglycemia.
  • •When insulin and C-peptide are both suppressed, evaluate for non-islet cell tumor hypoglycemia (NICTH): measure total IGF-1, total IGF-2, and the high-molecular-weight 'big' IGF-2. A ratio of big IGF-2 to total IGF-2 >0.2 is diagnostic. Also consider adrenal insufficiency (morning cortisol <3 μg/dL [83 nmol/L] or poor response to cosyntropin 250 μg), growth hormone deficiency (low IGF-1 with low GH), and inborn errors of metabolism (fasting hypoglycemia with lactic acidosis, ketosis, or fatty liver).
  • •Continuous glucose monitoring (CGM) is recommended for all individuals with diabetes at high risk for hypoglycemia, particularly those with a history of Level 3 events or hypoglycemia unawareness. CGM metrics, time below range (TBR) <70 mg/dL (<4% of time) and <54 mg/dL (TBR2), independently predict future severe hypoglycemia; each 1% increase in TBR2 is associated with a 15% higher relative risk (HR 1.15, 95% CI 1.08-1.23).

Management

  • •For acute mild-to-moderate hypoglycemia in a conscious patient able to swallow, administer 15-20 g of oral glucose, 3-4 glucose tablets, 4-6 oz (120-180 mL) fruit juice, or 1 tablespoon (15 g) sugar dissolved in water. Recheck capillary glucose in 15 minutes; if still <70 mg/dL (3.9 mmol/L), repeat the same dose. This 'Rule of 15' is the cornerstone of acute self-management.
  • •For severe hypoglycemia (altered mental status, seizure, or unconsciousness), administer glucagon 1 mg intramuscularly (IM), subcutaneously (SC), or intravenously (IV), 0.5 mg for children <25 kg or <5 years old. Onset of action is 5-15 minutes. Alternatively, give IV dextrose 50% (D50) 25 g (50 mL) in adults, or 0.5-1 g/kg as D25 (2 mL/kg) in children; onset is 1-3 minutes. Glucagon is preferred in out-of-hospital settings because it does not require IV access.
  • •After initial correction, recheck glucose every 15 minutes until stable >70 mg/dL, then every 1-2 hours for 4-6 hours to detect recurrence. In hospitalized patients, continuous glucose monitoring (CGM) reduces time spent in hypoglycemia compared with point-of-care testing alone; the TIGHT trial (2025) showed non-ICU patients had increased time in range without increased severe hypoglycemia.
  • •If glucose remains <70 mg/dL after two doses of dextrose or glucagon, initiate a continuous IV dextrose infusion, D10 at 50-100 mL/h, titrated to maintain glucose 100-150 mg/dL (5.6-8.3 mmol/L). For suspected sulfonylurea overdose, administer octreotide 50-100 mcg SC or IV every 6-12 hours to suppress endogenous insulin secretion; octreotide blocks calcium-dependent insulin release and can prevent recurrent hypoglycemia for 6-12 hours per dose.
  • •Once glucose is stable >70 mg/dL for 4-6 hours, transition to oral carbohydrates and resume the patient’s usual diabetes medications with appropriate dose reductions, typically reduce insulin doses by 20-50% depending on severity of the precipitating event. Provide education on sick-day rules, medication adjustment, and the importance of never skipping meals.
  • •For long-term prevention in insulin-treated type 2 diabetes, optimize the regimen: consider switching from sulfonylureas to safer agents (DPP-4 inhibitors, SGLT2 inhibitors, or GLP-1 receptor agonists) to reduce hypoglycemia risk. In type 1 diabetes, a hybrid closed-loop (automated insulin delivery, AID) system reduces HbA1c by 0.5-0.9 percentage points and severe hypoglycemia by 50% (RR 0.50, 95% CI 0.30-0.83) compared with conventional therapy.
  • •For insulinoma (preoperative medical management): start diazoxide 3-8 mg/kg/day orally in two to three divided doses (adults: 50-75 mg twice daily, titrate up to 150-200 mg three times daily; maximum 400 mg/day). Monitor for fluid retention (requires concomitant thiazide diuretic in up to 40%), hirsutism, and leukopenia. If refractory, consider pasireotide 0.6-0.9 mg SC twice daily, it reduces hypoglycemia episodes by 50-80% in case series.
  • •For post-bariatric hypoglycemia (PBH) not controlled by dietary modification (low glycemic index meals, small frequent meals) and acarbose 50-100 mg with meals, consider avexitide (exendin-9,39) 30 mg SC twice daily. The PREVENT trial showed avexitide raised postprandial glucose nadir from 55 to 68 mg/dL and reduced hypoglycemia event rate by 67%.
  • •For congenital hyperinsulinism (CHI): first-line therapy is diazoxide 5-15 mg/kg/day (maximum 20 mg/kg/day); if responsive, continue. Second-line is octreotide 5-20 μg/kg/day SC every 6-8 hours; if refractory, lanreotide 30-120 mg IM every 4 weeks. Genotype correlates with response: ABCC8/KCNJ11 mutations limited to one allele (focal disease) are more likely to respond to diazoxide than biallelic mutations (diffuse disease). For focal CHI, laparoscopic or open resection is curative in >95% of cases.
  • •In critically ill patients, target glucose 140-180 mg/dL (7.8-10.0 mmol/L). Avoid intensive targets (80-110 mg/dL), NICE-SUGAR demonstrated harm (HR 1.14, 95% CI 1.02-1.28; number needed to treat [NNT] = 38 to cause one excess death). Use IV insulin infusion with frequent monitoring (hourly point-of-care or CGM) and a validated titration protocol.
  • •Do not use sulfonylureas to manage hyperinsulinemic hypoglycemia, they will worsen it. Do not use prophylactic short-acting insulin in non-insulin-deficient patients. Do not discharge a patient with severe hypoglycemia without identifying the precipitating cause and providing a prevention plan. Do not use insulin to treat hypoglycemia.
  • •Refer to endocrinology for: all cases of confirmed or suspected insulinoma, congenital hyperinsulinism, post-bariatric hypoglycemia refractory to dietary modification, insulin autoimmune syndrome, Type B insulin resistance syndrome, non-islet cell tumor hypoglycemia, and recurrent severe hypoglycemia of uncertain etiology. Refer to bariatric surgery for PBH refractory to medical therapy. Refer to genetics for persistent neonatal hypoglycemia or syndromic presentations (e.g., MEN1, Wolfram syndrome).
  • •The Endocrine Society recommends that all patients at risk for severe hypoglycemia (those on insulin or sulfonylureas) have a glucagon prescription and a written action plan. Structured education programs (DAFNE, BGAT) reduce severe hypoglycemia rates by 50-60%. Hypoglycemia awareness restoration training, strict avoidance of hypoglycemia for 2-3 weeks, can restore counter-regulatory responses.
  • •In older adults (≥65 years), de-escalate sulfonylureas and insulin if HbA1c is consistently <7.0% or if the patient has frequent hypoglycemia. Target a less stringent HbA1c (<8.0% or <8.5%) to minimize risk. Continuous glucose monitoring reduces time below range by a mean of 1.2 hours/day in this population.
  • •In chronic kidney disease (CKD), reduce insulin doses by 25-50% on dialysis days; avoid sulfonylureas with long half-lives (e.g., glyburide). Use glucose-containing dialysate (100-200 mg/dL) during hemodialysis to reduce intradialytic hypoglycemia by 40% (RR 0.60, 95% CI 0.45-0.80).
  • •In neonates at risk (preterm, SGA, LGA, maternal diabetes), screen blood glucose at 1, 2, 4, 6, 12, and 24 hours of life. Prophylactic 40% dextrose gel (200 mg/kg) reduces NICU admission for hypoglycemia (RR 0.73, 95% CI 0.57-0.93; NNT = 10). For persistent neonatal hypoglycemia beyond 48 hours, evaluate for hyperinsulinism and start diazoxide 5-15 mg/kg/day after baseline echocardiography to exclude pulmonary hypertension.

Board Review — High Yield

  • •Whipple's triad, hypoglycemia diagnosis requires three elements: symptoms of hypoglycemia, low plasma glucose, and resolution of symptoms after glucose administration.
  • •ADA Level 2 hypoglycemia, glucose <54 mg/dL (3.0 mmol/L); this is the threshold that reliably predicts neuroglycopenic symptoms and autonomic activation.
  • •72-hour fast, gold standard for diagnosing insulinoma (sensitivity 95%). Terminate when glucose <45 mg/dL with symptoms or <50 mg/dL without symptoms after 72 hours.
  • •Rule of 15, acute management: 15 g oral glucose, recheck in 15 minutes, repeat if still <70 mg/dL.
  • •Octreotide, drug of choice for sulfonylurea overdose (50-100 mcg SC/IV q6-12h); suppresses endogenous insulin secretion.
  • •Insulinoma, most common cause of endogenous hyperinsulinemic hypoglycemia in non-diabetic adults; 5-10% malignant; localized by triple-phase CT, EUS, or GLP-1 receptor PET/CT.
  • •Diazoxide, first-line medical therapy for insulinoma and congenital hyperinsulinism; opens KATP channels on beta cells, inhibiting insulin release.
  • •NICE-SUGAR, landmark trial showing intensive glucose control (81-108 mg/dL) in ICU increased mortality vs. liberal target (<180 mg/dL) (HR 1.14).
  • •Hypoglycemia-associated autonomic failure (HAAF), recurrent hypoglycemia blunts counter-regulatory responses; strict avoidance of hypoglycemia for 2-3 weeks restores awareness.
  • •ABCC8/KCNJ11 mutations, most common genetic cause of congenital hyperinsulinism; diazoxide responsiveness is genotype-dependent.

Deep Dive — Evidence Details

References

  1. [1]

    Munshi MN, Florez H, Huang ES et al.. “Management of Diabetes in Long-term Care and Skilled Nursing Facilities: A Position Statement of the American Diabetes Association.” Diabetes care (2016). PMID: 26798150 ↗

    L1GUIDELINECited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification
  2. [2]

    Echouffo-Tcheugui JB, Kaze AD, Fonarow GC et al.. “Severe Hypoglycemia and Incident Heart Failure Among Adults With Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 34741460 ↗

    L2RCTCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors
  3. [3]

    Rossi A, Venema A, Haarsma P et al.. “A Prospective Study on Continuous Glucose Monitoring in Glycogen Storage Disease Type Ia: Toward Glycemic Targets.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35786777 ↗

    L2TRIAL_NONRANDOMCited in: Definition, Classification and Axis Nomenclature
  4. [4]

    Heller SR, Buse JB, Ratner R et al.. “Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes.” Diabetes care (2019). PMID: 31658975 ↗

    L2TRIAL_NONRANDOMCited in: Definition, Classification and Axis Nomenclature
  5. [5]

    Christiaens A, Boureau AS, Guyomarch B et al.. “Diabetes Overtreatment and Hypoglycemia in Older Patients With Type 2 Diabetes on Insulin Therapy: Insights From the HYPOAGE Cohort Study.” Diabetes care (2025). PMID: 39172937 ↗

    L2COHORTCited in: Definition, Classification and Axis Nomenclature
  6. [6]

    Vezzosi D, Cardot-Bauters C, Bouscaren N et al.. “Long-term results of the surgical management of insulinoma patients with MEN1: a Groupe d'étude des Tumeurs Endocrines (GTE) retrospective study.” European journal of endocrinology (2014). PMID: 25538206 ↗

    L3COHORTCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification, Complications and Long-term Sequelae
  7. [7]

    Eriksson O, Velikyan I, Selvaraju RK et al.. “Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report.” The Journal of clinical endocrinology and metabolism (2014). PMID: 24512490 ↗

    L4CASE_REPORTCited in: Definition, Classification and Axis Nomenclature
  8. [8]

    Liu H, Liang S, Li Y et al.. “A Novel Type of Extreme Insulin Resistance: Nonhypoglycemic Insulin Autoimmune Syndrome.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33382420 ↗

    L4CASE_REPORTCited in: Definition, Classification and Axis Nomenclature
  9. [9]

    Salehi M, Vella A, McLaughlin T et al.. “Hypoglycemia After Gastric Bypass Surgery: Current Concepts and Controversies.” The Journal of clinical endocrinology and metabolism (2018). PMID: 30101281 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Axis Physiology, Pathophysiology and Biochemical Signature
  10. [10]

    Verhoeff K, Marfil-Garza BA, Czarnecka Z et al.. “Stem Cell-Derived Islet Transplantation in Patients With Type 2 Diabetes: Can Diabetes Subtypes Guide Implementation?” The Journal of clinical endocrinology and metabolism (2023). PMID: 37170783 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature
  11. [11]

    Schwartz SS, Epstein S, Corkey BE et al.. “The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema.” Diabetes care (2016). PMID: 26798148 ↗

    L5OTHERCited in: Definition, Classification and Axis Nomenclature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  12. [12]

    He Y, Ma RCW, McIntyre HD et al.. “Comparing IADPSG and NICE Diagnostic Criteria for GDM in Predicting Adverse Pregnancy Outcomes.” Diabetes care (2022). PMID: 35880808 ↗

    L2OTHERCited in: Definition, Classification and Axis Nomenclature
  13. [13]

    Shanik MH, Xu Y, Skrha J et al.. “Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse?” Diabetes care (2008). PMID: 18227495 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  14. [14]

    Dauben L, Simon MC, Strassburger K et al.. “Comparison of the diagnostic accuracy of the current guidelines for detecting insulinoma.” European journal of endocrinology (2019). PMID: 30991361 ↗

    L3OTHERCited in: Definition, Classification and Axis Nomenclature
  15. [15]

    Crowther CA, Samuel D, McCowan LME et al.. “Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes.” The New England journal of medicine (2022). PMID: 36070709 ↗

    L1OTHERCited in: Definition, Classification and Axis Nomenclature
  16. [16]

    Yao B, Liu JY, Liu Y et al.. “Sequential versus continuous feeding and its effect on the gut microbiota in critically ill patients: A randomized controlled trial.” Clinical nutrition ESPEN (2025). PMID: 39798866 ↗

    L1RCTCited in: Definition, Classification and Axis Nomenclature
  17. [17]

    Craig CM, Ramanujan S, McLaughlin TL. “Prevalence of post-bariatric hypoglycemia in the United States.” Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery (2026). PMID: 41966914 ↗

    L2SR_OBSCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification
  18. [18]

    Shivaswamy V, Boerner B, Larsen J. “Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes.” Endocrine reviews (2015). PMID: 26650437 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  19. [19]

    Gupta N, Bruschettini M, Chawla D. “Fluid restriction in the management of transient tachypnea of the newborn.” The Cochrane database of systematic reviews (2021). PMID: 33599990 ↗

    L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  20. [20]

    Quezada DZA, Velásquez Porras PC, Aranda AON et al.. “Glycemic Risk Across Exercise Modalities in Adults with Type 1 Diabetes Using Continuous Glucose Monitoring and Wearable Sensors: A Prospective Cohort Study.” Journal of functional morphology and kinesiology (2026). PMID: 42346760 ↗

    L2COHORTCited in: Definition, Classification and Axis Nomenclature, Acute Management and Endocrine Emergencies
  21. [21]

    Yap F, Chan D, Zheng RT et al.. “Glucose Levels in At-risk Newborns (GLEAN): a prospective cohort study on glucose profiles in infants at risk of hypoglycemia.” Frontiers in endocrinology (2025). PMID: 40862109 ↗

    L2COHORTCited in: Definition, Classification and Axis Nomenclature
  22. [22]

    Gao X, Liu F, Han X et al.. “A Randomized Controlled Study on the Clinical Efficacy of Ginkgo Biloba Combined with Nicorandil in Patients with HFmrEF.” International heart journal (2025). PMID: 39894554 ↗

    L1RCTCited in: Definition, Classification and Axis Nomenclature
  23. [23]

    Ramachandran S, Kundra P, Velayudhan S et al.. “Effects of Prolonged Preoperative Fasting on Blood Glucose Levels in Pediatric Elective Surgeries: A Systematic Review and Meta-Analysis.” Paediatric anaesthesia (2026). PMID: 41795161 ↗

    L1SR_OBSCited in: Definition, Classification and Axis Nomenclature
  24. [24]

    Zhang B, Cheng Z, Chen J et al.. “Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.” Diabetes care (2024). PMID: 37943529 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  25. [25]

    Nauck MA, Petrie JR, Sesti G et al.. “A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.” Diabetes care (2015). PMID: 26358288 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  26. [26]

    Boeder SC, Thomas RL, Le Roux MJ et al.. “Combination SGLT2 Inhibitor and Glucagon Receptor Antagonist Therapy in Type 1 Diabetes: A Randomized Clinical Trial.” Diabetes care (2025). PMID: 38776437 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Acute Management and Endocrine Emergencies
  27. [27]

    Ferrannini E, Ramos SJ, Salsali A et al.. “Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.” Diabetes care (2010). PMID: 20566676 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  28. [28]

    Hepprich M, Romberg C, Mudry J et al.. “Exenatide for diagnosing endogenous hyperinsulinemic hypoglycemia: a randomized placebo-controlled, double-blind, cross-over proof-of-principle study.” European journal of endocrinology (2025). PMID: 40747712 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  29. [29]

    Almby KE, Abrahamsson N, Lundqvist MH et al.. “Effects of GLP-1 on counter-regulatory responses during hypoglycemia after GBP surgery.” European journal of endocrinology (2019). PMID: 31176298 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  30. [30]

    Murakami T, Yoshida H, Sakaki K et al.. “Qualitative and Quantitative Analyses of Noninvasive Diagnosis of Insulinoma Using [18F]FB(ePEG12)12-Exendin-4 PET/CT.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40391925 ↗

    L3TRIAL_NONRANDOMCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  31. [31]

    Brown N, Elston MS. “Systematic Review-Type B Insulin Resistance With Isolated Hypoglycemia and Suppressed Insulin.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37552775 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  32. [32]

    Lee MMY, Sattar N, Pop-Busui R et al.. “Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials.” Diabetes care (2025). PMID: 40156846 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae
  33. [33]

    Huthmacher JA, Meier JJ, Nauck MA. “Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis.” Diabetes care (2020). PMID: 32910778 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  34. [34]

    Frías JP, Davies MJ, Rosenstock J et al.. “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.” The New England journal of medicine (2021). PMID: 34170647 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  35. [35]

    Rosenstock J, Hsia S, Nevarez Ruiz L et al.. “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.” The New England journal of medicine (2025). PMID: 40544435 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  36. [36]

    Nathan DM, Lachin JM, Balasubramanyam A et al.. “Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.” The New England journal of medicine (2022). PMID: 36129996 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  37. [37]

    Lee TTM, Collett C, Bergford S et al.. “Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes.” The New England journal of medicine (2023). PMID: 37796241 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Prognosis, Natural History, Special Populations and Prevention
  38. [38]

    Pfeffer MA, Claggett B, Diaz R et al.. “Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.” The New England journal of medicine (2015). PMID: 26630143 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
  39. [39]

    Larsen CM, Faulenbach M, Vaag A et al.. “Interleukin-1-receptor antagonist in type 2 diabetes mellitus.” The New England journal of medicine (2007). PMID: 17429083 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  40. [40]

    Bohula EA, Wiviott SD, McGuire DK et al.. “Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.” The New England journal of medicine (2018). PMID: 30145941 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  41. [41]

    Wysham C, Bajaj HS, Del Prato S et al.. “Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment.” The New England journal of medicine (2024). PMID: 39254740 ↗

    L1TRIAL_NONRANDOMCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  42. [42]

    Iqbal A, Zhou K, Kashyap SR et al.. “Early Post-Renal Transplant Hyperglycemia.” The Journal of clinical endocrinology and metabolism (2022). PMID: 34558599 ↗

    L5CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  43. [43]

    Willard D, Upadhyay J, Kim C et al.. “Diabetic Ketoacidosis Without Diabetes.” The Journal of clinical endocrinology and metabolism (2016). PMID: 27636019 ↗

    L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  44. [44]

    Bourdeau I, Oble S, Magne F et al.. “ARMC5 mutations in a large French-Canadian family with cortisol-secreting β-adrenergic/vasopressin responsive bilateral macronodular adrenal hyperplasia.” European journal of endocrinology (2016). PMID: 26604299 ↗

    L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention
  45. [45]

    Hofland J, Refardt JC, Feelders RA et al.. “Approach to the Patient: Insulinoma.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37925662 ↗

    L5OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention
  46. [46]

    Paschou SA, Dede AD, Anagnostis PG et al.. “Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management.” The Journal of clinical endocrinology and metabolism (2017). PMID: 28938433 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae
  47. [47]

    Samuels ME, Gallo-Payet N, Pinard S et al.. “Bioinactive ACTH causing glucocorticoid deficiency.” The Journal of clinical endocrinology and metabolism (2013). PMID: 23293326 ↗

    L4OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  48. [48]

    Tuttle KR, Bakris GL, Bilous RW et al.. “Diabetic kidney disease: a report from an ADA Consensus Conference.” Diabetes care (2014). PMID: 25249672 ↗

    L1OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae
  49. [49]

    Cernea S, Raz I. “Therapy in the early stage: incretins.” Diabetes care (2011). PMID: 21525466 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
  50. [50]

    Fallahi P, Ferrari SM, Elia G et al.. “THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitors.” European journal of endocrinology (2021). PMID: 33112294 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  51. [51]

    Rosenfeld RG. “IGF-I therapy in growth disorders.” European journal of endocrinology (2007). PMID: 17785699 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  52. [52]

    Iglesias P, Díez JJ. “Management of endocrine disease: a clinical update on tumor-induced hypoglycemia.” European journal of endocrinology (2014). PMID: 24459236 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  53. [53]

    Hinrichs A, Renner S, Bidlingmaier M et al.. “MECHANISMS IN ENDOCRINOLOGY: Transient juvenile hypoglycemia in growth hormone receptor deficiency - mechanistic insights from Laron syndrome and tailored animal models.” European journal of endocrinology (2021). PMID: 34048365 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  54. [54]

    Verrotti A, Scaparrotta A, Olivieri C et al.. “Seizures and type 1 diabetes mellitus: current state of knowledge.” European journal of endocrinology (2012). PMID: 22956556 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
  55. [55]

    Zou M, Liu C. “Glucagon-like peptide-1 receptor agonists improve hepatic histology and metabolic parameters in type 2 diabetes with MASLD: a meta-analysis of randomized controlled trials.” Diabetology & metabolic syndrome (2026). PMID: 42121292 ↗

    L1SR_MA_RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  56. [56]

    Guo L, Sun Z, Zhang L et al.. “HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial.” JAMA network open (2026). PMID: 42234428 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  57. [57]

    Bugbee A, Rucinsky R, Alvarez E et al.. “2026 AAHA Diabetes Management Guidelines for Cats.” Journal of the American Animal Hospital Association (2026). PMID: 42014100 ↗

    L1GUIDELINECited in: Axis Physiology, Pathophysiology and Biochemical Signature
  58. [58]

    Eisa N, Barood O. “Effects of Semaglutide on Dumping Syndrome and Reactive Hypoglycemia After Bariatric Surgery: A Systematic Review and Meta-Analysis.” Obesity reviews : an official journal of the International Association for the Study of Obesity (2026). PMID: 42140745 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
  59. [59]

    Wójcik-Sosnowska E, Tabeau A, Pawlik A et al.. “Metabolic Benefits vs. Cardiovascular Uncertainty: A Critical Review of GLP-1 Receptor Agonists in Type 1 Diabetes.” International journal of molecular sciences (2026). PMID: 42123472 ↗

    L5SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae
  60. [60]

    Kanbay M, Abdel-Rahman SM, Guldan M et al.. “Clinical outcomes of glucagon-like peptide-1 receptor agonist therapy in kidney transplant recipients: a systematic review and meta-analysis.” Clinical kidney journal (2026). PMID: 42017027 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  61. [61]

    Zhu X, Wang X, Zhang P et al.. “Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysis.” Frontiers in endocrinology (2026). PMID: 41987895 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  62. [62]

    Noakes TD, Prins PJ, Buga A et al.. “Carbohydrate Ingestion on Exercise Metabolism and Physical Performance.” Endocrine reviews (2026). PMID: 41562187 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
  63. [63]

    Dynkevich Y, Rother KI, Whitford I et al.. “Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive.” Endocrine reviews (2013). PMID: 23671155 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  64. [64]

    Gromada J, Franklin I, Wollheim CB. “Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains.” Endocrine reviews (2007). PMID: 17261637 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
  65. [65]

    Kodl CT, Seaquist ER. “Cognitive dysfunction and diabetes mellitus.” Endocrine reviews (2008). PMID: 18436709 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  66. [66]

    Ussher JR, Drucker DJ. “Cardiovascular biology of the incretin system.” Endocrine reviews (2012). PMID: 22323472 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  67. [67]

    Marfil-Garza BA, Hefler J, Bermudez De Leon M et al.. “Progress in Translational Regulatory T Cell Therapies for Type 1 Diabetes and Islet Transplantation.” Endocrine reviews (2021). PMID: 33247733 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
  68. [68]

    Abdul-Ghani MA, Norton L, Defronzo RA. “Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.” Endocrine reviews (2011). PMID: 21606218 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors
  69. [69]

    Wu CY, Shah BR, Ezekowitz JA et al.. “Effectiveness and Safety of SGLT2 Inhibitor Initiation in Sacubitril-Valsartan Users with Heart Failure: A Population-Based Cohort Study.” European heart journal. Cardiovascular pharmacotherapy (2026). PMID: 42098937 ↗

    L2COHORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  70. [70]

    Cryer PE, Axelrod L, Grossman AB et al.. “Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline.” The Journal of clinical endocrinology and metabolism (2008). PMID: 19088155 ↗

    L1GUIDELINECited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  71. [71]

    Spanakis EK, Urrutia A, Galindo RJ et al.. “Continuous Glucose Monitoring-Guided Insulin Administration in Hospitalized Patients With Diabetes: A Randomized Clinical Trial.” Diabetes care (2022). PMID: 35984478 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  72. [72]

    Rosenstock J, Cheng A, Ritzel R et al.. “More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial.” Diabetes care (2018). PMID: 30104294 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  73. [73]

    Sweeting A, Enticott J, Immanuel J et al.. “Relationship Between Early-Pregnancy Glycemia and Adverse Outcomes: Findings From the TOBOGM Study.” Diabetes care (2024). PMID: 39083673 ↗

    L2RCTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  74. [74]

    Ren Q, Wang Z, Yang W et al.. “Maternal and Infant Outcomes in GCK-MODY Complicated by Pregnancy.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37011183 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention
  75. [75]

    Gerstein HC, Miller ME, Byington RP et al.. “Effects of intensive glucose lowering in type 2 diabetes.” The New England journal of medicine (2008). PMID: 18539917 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  76. [76]

    Patel A, MacMahon S, Chalmers J et al.. “Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.” The New England journal of medicine (2008). PMID: 18539916 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  77. [77]

    Kahn SE, Haffner SM, Heise MA et al.. “Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.” The New England journal of medicine (2006). PMID: 17145742 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  78. [78]

    Gunst J, Debaveye Y, Güiza F et al.. “Tight Blood-Glucose Control without Early Parenteral Nutrition in the ICU.” The New England journal of medicine (2023). PMID: 37754283 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae
  79. [79]

    Gyamfi-Bannerman C, Thom EA, Blackwell SC et al.. “Antenatal Betamethasone for Women at Risk for Late Preterm Delivery.” The New England journal of medicine (2016). PMID: 26842679 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention
  80. [80]

    Duckworth W, Abraira C, Moritz T et al.. “Glucose control and vascular complications in veterans with type 2 diabetes.” The New England journal of medicine (2008). PMID: 19092145 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  81. [81]

    Danner E, Jääskeläinen J, Niuro L et al.. “Comorbidity in Congenital Hypothyroidism-A Nationwide, Population-based Cohort Study.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37279943 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae
  82. [82]

    Han E, Han KD, Lee BW et al.. “Severe Hypoglycemia Increases Dementia Risk and Related Mortality: A Nationwide, Population-based Cohort Study.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35015886 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae
  83. [83]

    Velde CD, Molnes J, Berland S et al.. “Clinical and Genetic Characteristics of Congenital Hyperinsulinism in Norway: A Nationwide Cohort Study.” The Journal of clinical endocrinology and metabolism (2025). PMID: 38963811 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  84. [84]

    Helvacioglu D, Canbaz AT, Tekmenuray-Unal A et al.. “Primary adrenal insufficiency caused by pseudo-neonatal adrenoleukodystrophy associated with biallelic ACOX1 mutations.” European journal of endocrinology (2025). PMID: 40326779 ↗

    L4CASE_REPORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  85. [85]

    Umpierrez GE, Pasquel FJ. “Management of Inpatient Hyperglycemia and Diabetes in Older Adults.” Diabetes care (2017). PMID: 28325798 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  86. [86]

    Andersen A, Bagger JI, Baldassarre MPA et al.. “Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls.” European journal of endocrinology (2021). PMID: 34085953 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae
  87. [87]

    Galderisi A, Kariyawasam D, Stoupa A et al.. “Glucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring.” European journal of endocrinology (2023). PMID: 37952170 ↗

    L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  88. [88]

    Battezzati A, Battezzati PM, Costantini D et al.. “Spontaneous hypoglycemia in patients with cystic fibrosis.” European journal of endocrinology (2007). PMID: 17322497 ↗

    L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  89. [89]

    Karges B, Rosenbauer J, Holterhus PM et al.. “Hospital admission for diabetic ketoacidosis or severe hypoglycemia in 31,330 young patients with type 1 diabetes.” European journal of endocrinology (2015). PMID: 26088822 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae
  90. [90]

    Benhalima K, Van Crombrugge P, Moyson C et al.. “Risk factor screening for gestational diabetes mellitus based on the 2013 WHO criteria.” European journal of endocrinology (2019). PMID: 31120231 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History, Special Populations and Prevention
  91. [91]

    Cao H, Zhou Y, Gu N et al.. “Randomized controlled trial investigating the efficacy of oral azithromycin in preventing perinatal infections in pregnant women undergoing labor induction.” International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (2026). PMID: 42141927 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae
  92. [92]

    Cao J, Nie J, Wu D et al.. “Machine learning-based prediction models for severe Mycoplasma pneumoniae pneumonia in Chinese children: a systematic review and meta-analysis of prediction model performance.” Frontiers in public health (2026). PMID: 42318005 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention
  93. [93]

    Rusu C, Matyas M, Kramer BW et al.. “Neonatal Hypoglycemia: A Systematic Review of International and Local Clinical Guidelines with Clinical Implications.” Journal of clinical medicine (2026). PMID: 42194883 ↗

    L5SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention
  94. [94]

    Coșovanu EO, Szilagyi A, Szilagyi A et al.. “Advantages of Continuous and Non-Invasive Glucose Monitoring in the Geriatric Population: A Systematic Review.” Journal of clinical medicine (2026). PMID: 42122927 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  95. [95]

    Phillip M, Nimri R, Bergenstal RM et al.. “Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice.” Endocrine reviews (2023). PMID: 36066457 ↗

    L1OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae
  96. [96]

    Fineberg SE, Kawabata TT, Finco-Kent D et al.. “Immunological responses to exogenous insulin.” Endocrine reviews (2007). PMID: 17785428 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  97. [97]

    Trzaski JM, Cracknell J, Herbst KW et al.. “Insulin-like growth factor-1 for the prevention or treatment of retinopathy of prematurity.” The Cochrane database of systematic reviews (2026). PMID: 41983451 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  98. [98]

    Tack B, Vita D, Mbuyamba J et al.. “Non-typhoidal Salmonella co-infect and complsicate Plasmodium falciparum malaria in children under-five: A prospective cohort study on clinical presentation and outcome in Kisantu district hospital, DR Congo.” PLoS neglected tropical diseases (2026). PMID: 42341028 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  99. [99]

    Sharifi F, Abdolahpour S, Setoudeh A et al.. “Genotype-Treatment Correlations in Iranian Children with Congenital Hyperinsulinism: A Single-Center Cohort Study.” Hormone research in paediatrics (2026). PMID: 42301945 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  100. [100]

    Hirsch IB, Bode B, Courreges JP et al.. “Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.” Diabetes care (2012). PMID: 22933438 ↗

    L1RCTCited in: Clinical Presentation
  101. [101]

    Widmer A, Zumsteg U, Szinnai G et al.. “Congenital Hyperinsulinemic Hypoglycemia With a New HADH Mutation and Pancreatic Overexpression of GLP-1 Receptors.” The Journal of clinical endocrinology and metabolism (2026). PMID: 40705962 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  102. [102]

    Lal RA, Bachrach LK, Hoffman AR et al.. “A Case Report of Hypoglycemia and Hypogammaglobulinemia: DAVID Syndrome in a Patient With a Novel NFKB2 Mutation.” The Journal of clinical endocrinology and metabolism (2017). PMID: 28472507 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  103. [103]

    Elhomsy GC, Eranki V, Albert SG et al.. “"Hyper-warburgism," a cause of asymptomatic hypoglycemia with lactic acidosis in a patient with non-Hodgkin's lymphoma.” The Journal of clinical endocrinology and metabolism (2012). PMID: 23055548 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  104. [104]

    Ismail D, Kapoor RR, Smith VV et al.. “The heterogeneity of focal forms of congenital hyperinsulinism.” The Journal of clinical endocrinology and metabolism (2011). PMID: 22031516 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  105. [105]

    De Bellis A, Colella C, Bellastella G et al.. “Late primary autoimmune hypothyroidism in a patient with postdelivery autoimmune hypopituitarism associated with antibodies to growth hormone and prolactin-secreting cells.” Thyroid : official journal of the American Thyroid Association (2013). PMID: 23286389 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention
  106. [106]

    Dhanasekaran M, Mohan S, Erickson D et al.. “Diabetic Ketoacidosis in Pregnancy: Clinical Risk Factors, Presentation, and Outcomes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35917830 ↗

    L2OTHERCited in: Clinical Presentation, Acute Management and Endocrine Emergencies
  107. [107]

    Hopkins JJ, Childs AJ, Houghton JAL et al.. “Hyperinsulinemic Hypoglycemia Diagnosed in Childhood Can Be Monogenic.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36239000 ↗

    L3OTHERCited in: Clinical Presentation
  108. [108]

    Zhao L, Li W, Liu L et al.. “Clinical Features and Outcome Analysis of Type B Insulin Resistance Syndrome: A Single-Center Study in China.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37536271 ↗

    L4OTHERCited in: Clinical Presentation
  109. [109]

    Petrelli A, Thomas NJ, Hope SV et al.. “Pathophysiology and Treatment of Type 1 Diabetes in Older Adults.” Diabetes care (2026). PMID: 42237872 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  110. [110]

    Lin YK, Richardson CR, Dobrin I et al.. “Beliefs Around Hypoglycemia and Their Impacts on Hypoglycemia Outcomes in Individuals with Type 1 Diabetes and High Risks for Hypoglycemia Despite Using Advanced Diabetes Technologies.” Diabetes care (2022). PMID: 35015079 ↗

    L3OTHERCited in: Clinical Presentation
  111. [111]

    Redondo MJ, Libman I, Cheng P et al.. “Racial/Ethnic Minority Youth With Recent-Onset Type 1 Diabetes Have Poor Prognostic Factors.” Diabetes care (2018). PMID: 29496742 ↗

    L2OTHERCited in: Clinical Presentation
  112. [112]

    Rafiq M, Flanagan SE, Patch AM et al.. “Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations.” Diabetes care (2007). PMID: 18025408 ↗

    L2OTHERCited in: Clinical Presentation
  113. [113]

    Lim DBN, Bryce J, Ali SR et al.. “Contemporary global management of 21-hydroxylase deficiency congenital adrenal hyperplasia in early infancy: a multi-national registry study.” European journal of endocrinology (2026). PMID: 41531283 ↗

    L2OTHERCited in: Clinical Presentation, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention
  114. [114]

    Boodhansingh KE, Yang Z, Li C et al.. “Localized islet nuclear enlargement hyperinsulinism (LINE-HI) due to ABCC8 and GCK mosaic mutations.” European journal of endocrinology (2022). PMID: 35674212 ↗

    L4OTHERCited in: Clinical Presentation
  115. [115]

    van Oldenmark BO, van Steenis A, van der Aa NE et al.. “Perinatal arterial ischemic stroke (PAIS) and neonatal cerebral sinovenous thrombosis (CSVT) in the preterm neonate: a systematic review.” Pediatric research (2026). PMID: 41680509 ↗

    L1SR_OBSCited in: Clinical Presentation
  116. [116]

    Sinclair JC, Bottino M, Cowett RM. “Interventions for prevention of neonatal hyperglycemia in very low birth weight infants.” The Cochrane database of systematic reviews (2011). PMID: 21975772 ↗

    L1SR_OBSCited in: Clinical Presentation, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  117. [117]

    Sinclair JC, Bottino M, Cowett RM. “Interventions for prevention of neonatal hyperglycemia in very low birth weight infants.” The Cochrane database of systematic reviews (2009). PMID: 19588439 ↗

    L1SR_OBSCited in: Clinical Presentation, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  118. [118]

    Jiang L, Shao H, Wang X et al.. “Early Pregnancy Triglyceride to HDL-C Ratio Predicts Gestational Diabetes Mellitus and Neonatal Hypoglycemia: A Retrospective Cohort Study.” Diabetes, metabolic syndrome and obesity : targets and therapy (2026). PMID: 42004934 ↗

    L2COHORTCited in: Clinical Presentation
  119. [119]

    Ngo EMT, Rowe JM, Chillon TS et al.. “Type B insulin resistance with glycemic extremes: a case report and literature review.” Frontiers in endocrinology (2026). PMID: 42255432 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  120. [120]

    Kraft BD, Matuszak S. “Angioedema After Accidental Semaglutide Dosing Error: A Case Report.” Journal of clinical medicine (2026). PMID: 42194666 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  121. [121]

    Sanders VR, Lord K, Sigal W et al.. “Double Trouble: When Focal and Diffuse Hyperinsulinism Occur Simultaneously.” Hormone research in paediatrics (2026). PMID: 41795819 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  122. [122]

    Karkalemis K, Papadopoulou-Marketou N, Kalampokas E et al.. “Ovarian stimulation toward oocyte cryopreservation for fertility preservation in a patient with Hirata syndrome: a clinical challenge in assisted reproduction.” Archives of gynecology and obstetrics (2026). PMID: 41652049 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  123. [123]

    McCall AL, Lieb DC, Gianchandani R et al.. “Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36477488 ↗

    L1GUIDELINECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  124. [124]

    Seisa MO, Saadi S, Nayfeh T et al.. “A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline for the Management of Hyperglycemia in Adults Hospitalized for Noncritical Illness or Undergoing Elective Surgical Procedures.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35690929 ↗

    L1GUIDELINECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  125. [125]

    Brar PC, Heksch R, Cossen K et al.. “Management and Appropriate Use of Diazoxide in Infants and Children with Hyperinsulinism.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32810255 ↗

    L5GUIDELINECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Prognosis, Natural History, Special Populations and Prevention
  126. [126]

    Uhl S, Choure A, Rouse B et al.. “Effectiveness of Continuous Glucose Monitoring on Metrics of Glycemic Control in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37987208 ↗

    L1SR_MA_RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies
  127. [127]

    Luo Y, Wang J, Sun L et al.. “Isocaloric-restricted Mediterranean Diet and Chinese Diets High or Low in Plants in Adults With Prediabetes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35579171 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  128. [128]

    Obermayer A, Tripolt NJ, Pferschy PN et al.. “Efficacy and Safety of Intermittent Fasting in People With Insulin-Treated Type 2 Diabetes (INTERFAST-2)-A Randomized Controlled Trial.” Diabetes care (2023). PMID: 36508320 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  129. [129]

    Yew TW, Chi C, Chan SY et al.. “A Randomized Controlled Trial to Evaluate the Effects of a Smartphone Application-Based Lifestyle Coaching Program on Gestational Weight Gain, Glycemic Control, and Maternal and Neonatal Outcomes in Women With Gestational Diabetes Mellitus: The SMART-GDM Study.” Diabetes care (2020). PMID: 33184151 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  130. [130]

    . “A Randomized Clinical Trial Assessing Continuous Glucose Monitoring (CGM) Use With Standardized Education With or Without a Family Behavioral Intervention Compared With Fingerstick Blood Glucose Monitoring in Very Young Children With Type 1 Diabetes.” Diabetes care (2020). PMID: 33334807 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  131. [131]

    Hirsch IB, Draznin B, Buse JB et al.. “Results From a Randomized Trial of Intensive Glucose Management Using CGM Versus Usual Care in Hospitalized Adults With Type 2 Diabetes: The TIGHT Study.” Diabetes care (2025). PMID: 39571106 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies
  132. [132]

    Bajaj HS, Ásbjörnsdóttir B, Carstensen L et al.. “Continuous Glucose Monitoring-Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4.” Diabetes care (2024). PMID: 38380954 ↗

    L2RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  133. [133]

    Kudva YC, Raghinaru D, Lum JW et al.. “A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes.” The New England journal of medicine (2025). PMID: 40105270 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  134. [134]

    Wadwa RP, Reed ZW, Buckingham BA et al.. “Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes.” The New England journal of medicine (2023). PMID: 36920756 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies
  135. [135]

    Landon MB, Spong CY, Thom E et al.. “A multicenter, randomized trial of treatment for mild gestational diabetes.” The New England journal of medicine (2009). PMID: 19797280 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History, Special Populations and Prevention
  136. [136]

    Russell SJ, Beck RW, Damiano ER et al.. “Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes.” The New England journal of medicine (2022). PMID: 36170500 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies
  137. [137]

    Leelarathna L, Evans ML, Neupane S et al.. “Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes.” The New England journal of medicine (2022). PMID: 36198143 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  138. [138]

    Boughton CK, Allen JM, Ware J et al.. “Closed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes.” The New England journal of medicine (2022). PMID: 36069870 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  139. [139]

    Ludvigsson J, Krisky D, Casas R et al.. “GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.” The New England journal of medicine (2012). PMID: 22296077 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  140. [140]

    Shah VN, DuBose SN, Li Z et al.. “Continuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study.” The Journal of clinical endocrinology and metabolism (2019). PMID: 31127824 ↗

    L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  141. [141]

    Oskarsson P, Antuna R, Geelhoed-Duijvestijn P et al.. “Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial.” Diabetologia (2017). PMID: 29273897 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention
  142. [142]

    Morioka T, Ohba K, Morita H et al.. “Non-islet cell tumor-induced hypoglycemia associated with macronodular pulmonary metastases from poorly differentiated thyroid carcinoma.” Thyroid : official journal of the American Thyroid Association (2013). PMID: 23697382 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  143. [143]

    Di Candia S, Gessi A, Pepe G et al.. “Identification of a diffuse form of hyperinsulinemic hypoglycemia by 18-fluoro-L-3,4 dihydroxyphenylalanine positron emission tomography/CT in a patient carrying a novel mutation of the HADH gene.” European journal of endocrinology (2009). PMID: 19318379 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History, Special Populations and Prevention
  144. [144]

    Nwokolo M, Hovorka R. “The Artificial Pancreas and Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36734145 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  145. [145]

    Danne T, Nimri R, Battelino T et al.. “International Consensus on Use of Continuous Glucose Monitoring.” Diabetes care (2017). PMID: 29162583 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae
  146. [146]

    Holt RIG, DeVries JH, Hess-Fischl A et al.. “The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).” Diabetes care (2021). PMID: 34593612 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae
  147. [147]

    Flanagan SE, Kapoor RR, Mali G et al.. “Diazoxide-responsive hyperinsulinemic hypoglycemia caused by HNF4A gene mutations.” European journal of endocrinology (2010). PMID: 20164212 ↗

    L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention
  148. [148]

    Bonnet-Serrano F, Devin-Genteuil C, Thomeret L et al.. “C-peptide level concomitant with hypoglycemia gives better performances than insulin for the diagnosis of endogenous hyperinsulinism: a single-center study of 159 fasting trials.” European journal of endocrinology (2023). PMID: 36756737 ↗

    L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  149. [149]

    Martínez R, Fernández-Ramos C, Vela A et al.. “Clinical and genetic characterization of congenital hyperinsulinism in Spain.” European journal of endocrinology (2016). PMID: 27188453 ↗

    L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  150. [150]

    Sun Q, Zhao G. “The Efficacy and Safety of Teplizumab in the Treatment of Stage 3 Type 1 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Diabetes, metabolic syndrome and obesity : targets and therapy (2026). PMID: 42221148 ↗

    L1SR_MA_RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies
  151. [151]

    Siegelaar SE, Holleman F, Hoekstra JB et al.. “Glucose variability; does it matter?” Endocrine reviews (2009). PMID: 19966012 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  152. [152]

    Finken MJJ, van der Steen M, Smeets CCJ et al.. “Children Born Small for Gestational Age: Differential Diagnosis, Molecular Genetic Evaluation, and Implications.” Endocrine reviews (2018). PMID: 29982551 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  153. [153]

    Bruschettini M, Badura A, Romantsik O. “Stem cell-based interventions for the treatment of stroke in newborn infants.” The Cochrane database of systematic reviews (2023). PMID: 37994736 ↗

    L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  154. [154]

    Onady GM, Stolfi A. “Drug treatments for managing cystic fibrosis-related diabetes.” The Cochrane database of systematic reviews (2020). PMID: 33075159 ↗

    L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  155. [155]

    Onady GM, Stolfi A. “Insulin and oral agents for managing cystic fibrosis-related diabetes.” The Cochrane database of systematic reviews (2016). PMID: 27087121 ↗

    L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  156. [156]

    Onady GM, Stolfi A. “Insulin and oral agents for managing cystic fibrosis-related diabetes.” The Cochrane database of systematic reviews (2013). PMID: 23893261 ↗

    L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  157. [157]

    Herranz-Antolín S, Gómez-Peralta F, Yongjin X et al.. “Increased Glycation Ratio and Risk of Complications in Latent Autoimmune Diabetes in Adults Compared With Type 1 Diabetes Onset before 30 Years: A Cohort Study.” Diabetes technology & therapeutics (2026). PMID: 42210521 ↗

    L4COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  158. [158]

    Piccolo C, de Candia S, Natalicchio A et al.. “Phenylketonuria and type 1 diabetes: a clinical and nutritional challenge in a young adult-a case report.” Acta diabetologica (2026). PMID: 42319439 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  159. [159]

    Ahmed F, Khan S, Gohar N et al.. “Clinical Outcomes of GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination Therapy in Heart Failure: A Real-World Propensity-Matched TriNetX Analysis.” Biomedicines (2026). PMID: 42351796 ↗

    L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  160. [160]

    Khalafalla HE, Albasheer O, Elfaki FA et al.. “Diabetes-related stigma among individuals with type 1 diabetes in Jazan, Saudi Arabia: sociodemographic and clinical correlates.” Frontiers in endocrinology (2026). PMID: 42339084 ↗

    L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  161. [161]

    Forțofoiu D, Sacerdoțianu VM, Șerban RE et al.. “Paraneoplastic Endocrine Changes in Gastrointestinal Tumors: A Clinical and Mechanistic Review.” International journal of molecular sciences (2026). PMID: 42278207 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  162. [162]

    Klonoff DC, Buckingham B, Christiansen JS et al.. “Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline.” The Journal of clinical endocrinology and metabolism (2011). PMID: 21976745 ↗

    L1GUIDELINECited in: Severity, Staging and Risk Stratification
  163. [163]

    Frias JP, Choi J, Rosenstock J et al.. “Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial.” Diabetes care (2022). PMID: 35671039 ↗

    L1RCTCited in: Severity, Staging and Risk Stratification
  164. [164]

    Montaser E, Williams C, Shah VN. “Assessing Time Below Range as a Predictor of Severe Hypoglycemia: Insights From Six Clinical Trials.” Diabetes care (2026). PMID: 41529164 ↗

    L2TRIAL_NONRANDOMCited in: Severity, Staging and Risk Stratification
  165. [165]

    Torres Roldan VD, Urtecho M, Nayfeh T et al.. “A Systematic Review Supporting the Endocrine Society Guidelines: Management of Diabetes and High Risk of Hypoglycemia.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36477885 ↗

    L1SR_OBSCited in: Severity, Staging and Risk Stratification
  166. [166]

    Lundemose SB, Ranjan AG, Nørgaard O et al.. “Low-Dose Glucagon to Prevent and Treat Exercise-Associated Hypoglycemia in Individuals With Type 1 Diabetes: A Systematic Review and Meta-analysis.” Diabetes care (2025). PMID: 40834249 ↗

    L1SR_OBSCited in: Severity, Staging and Risk Stratification
  167. [167]

    Rosenstock J, Bajaj HS, Janež A et al.. “Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.” The New England journal of medicine (2020). PMID: 32960514 ↗

    L1RCTCited in: Severity, Staging and Risk Stratification
  168. [168]

    Agus MS, Wypij D, Hirshberg EL et al.. “Tight Glycemic Control in Critically Ill Children.” The New England journal of medicine (2017). PMID: 28118549 ↗

    L1RCTCited in: Severity, Staging and Risk Stratification
  169. [169]

    Pasquel FJ, Tsegka K, Wang H et al.. “Clinical Outcomes in Patients With Isolated or Combined Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State: A Retrospective, Hospital-Based Cohort Study.” Diabetes care (2019). PMID: 31704689 ↗

    L2COHORTCited in: Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae
  170. [170]

    Lord K, De León DD. “Approach to the Neonate With Hypoglycemia.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38629854 ↗

    L5CASE_REPORTCited in: Severity, Staging and Risk Stratification, Prognosis, Natural History, Special Populations and Prevention
  171. [171]

    . “6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2025.” Diabetes care (2025). PMID: 39651981 ↗

    L1REVIEW_NARRATIVECited in: Severity, Staging and Risk Stratification
  172. [172]

    . “6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2024.” Diabetes care (2024). PMID: 38078586 ↗

    L1REVIEW_NARRATIVECited in: Severity, Staging and Risk Stratification
  173. [173]

    Ji L, Cheng Z, Ma J et al.. “HTD1801 in Combination with Metformin for Type 2 Diabetes.” NEJM evidence (2026). PMID: 42251702 ↗

    L1RCTCited in: Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  174. [174]

    Li Y, Chen J, Gao Y et al.. “Comparative Safety of SGLT2 Versus DPP4 Inhibitors in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.” Diabetes therapy : research, treatment and education of diabetes and related disorders (2026). PMID: 41678006 ↗

    L1SR_MA_RCTCited in: Severity, Staging and Risk Stratification
  175. [175]

    Albazee E, AlOtaibi A, Alsaffar H et al.. “Microneedling with Topical Insulin Versus Microneedling with Platelet-rich Plasma for Post-Acne Scars: A Systematic Review and Meta-Analysis with Trial Sequential Analysis.” Aesthetic plastic surgery (2026). PMID: 42324392 ↗

    L1SR_OBSCited in: Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  176. [176]

    Liu C, Mujahid O, Beneyto A et al.. “Sex differences in glycemic outcomes: a systematic review and meta-analysis of diabetes treatments.” BMJ open diabetes research & care (2026). PMID: 42020119 ↗

    L1SR_OBSCited in: Severity, Staging and Risk Stratification
  177. [177]

    Gilbert BW, Turpin BB, Murray DS et al.. “The Evaluation of Early Basal Insulin in Diabetic Ketoacidosis: A Systematic Review and Meta-Analysis.” Diabetes/metabolism research and reviews (2026). PMID: 41865288 ↗

    L1SR_OBSCited in: Severity, Staging and Risk Stratification
  178. [178]

    Zhou Z, Liu C, Xu Q et al.. “Effects of glucose-containing dialysates for patients with maintenance hemodialysis: a systematic review, pairwise and network meta-analysis.” Systematic reviews (2026). PMID: 41742316 ↗

    L1SR_OBSCited in: Severity, Staging and Risk Stratification
  179. [179]

    Umpierrez GE, Smiley D, Zisman A et al.. “Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial).” Diabetes care (2007). PMID: 17513708 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  180. [180]

    Rosenstock J, Marquard J, Laffel LM et al.. “Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.” Diabetes care (2018). PMID: 30287422 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  181. [181]

    Lauritzen ES, Voss T, Kampmann U et al.. “Circulating acylghrelin levels are suppressed by insulin and increase in response to hypoglycemia in healthy adult volunteers.” European journal of endocrinology (2015). PMID: 25599708 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies
  182. [182]

    Olsen MT, Liarakos AL, Wilmot EG et al.. “Implementation Strategies for Inpatient Continuous Glucose Monitoring-based Diabetes Management: A Systematic Review.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39918053 ↗

    L2SR_OBSCited in: Acute Management and Endocrine Emergencies
  183. [183]

    Finfer S, Chittock DR, Su SY et al.. “Intensive versus conventional glucose control in critically ill patients.” The New England journal of medicine (2009). PMID: 19318384 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  184. [184]

    Bhatt DL, Szarek M, Steg PG et al.. “Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.” The New England journal of medicine (2020). PMID: 33200892 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  185. [185]

    Burnside MJ, Lewis DM, Crocket HR et al.. “Open-Source Automated Insulin Delivery in Type 1 Diabetes.” The New England journal of medicine (2022). PMID: 36069869 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies
  186. [186]

    Taylor SI, Blau JE, Rother KI. “SGLT2 Inhibitors May Predispose to Ketoacidosis.” The Journal of clinical endocrinology and metabolism (2015). PMID: 26086329 ↗

    L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies
  187. [187]

    Prahalad P, Zaharieva D, Maahs DM. “Diabetes technology: an update.” The Journal of clinical endocrinology and metabolism (2026). PMID: 41973910 ↗

    L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae
  188. [188]

    Prinz N, Konrad K, Brack C et al.. “Diabetes care in pediatric refugees from Africa or Middle East: experiences from Germany and Austria based on real-world data from the DPV registry.” European journal of endocrinology (2019). PMID: 31075760 ↗

    L2OTHERCited in: Acute Management and Endocrine Emergencies, Prognosis, Natural History, Special Populations and Prevention
  189. [189]

    Odenwald B, Nennstiel-Ratzel U, Dörr HG et al.. “Children with classic congenital adrenal hyperplasia experience salt loss and hypoglycemia: evaluation of adrenal crises during the first 6 years of life.” European journal of endocrinology (2015). PMID: 26563979 ↗

    L4OTHERCited in: Acute Management and Endocrine Emergencies
  190. [190]

    Donovan LE, Lemieux P, Yamamoto JM et al.. “Intrapartum and Early Postpartum Use of Automated Insulin Delivery in Type 1 Diabetes: A Prespecified Analysis of the CIRCUIT Randomized Controlled Trial.” Diabetes care (2026). PMID: 42201836 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies, Prognosis, Natural History, Special Populations and Prevention
  191. [191]

    Olsen MT, Liarakos AL, Wilmot EG et al.. “Automated Insulin Delivery Systems in Hospitals: A Systematic Review with Meta-Analysis.” Diabetes technology & therapeutics (2026). PMID: 42338280 ↗

    L1SR_OBSCited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae
  192. [192]

    Felippe CA, Ruiz SDSC, de Souza RF et al.. “Antenatal Corticosteroid Use in Twin Pregnancies: A Systematic Review and Meta-analysis.” Obstetrics and gynecology (2026). PMID: 42241699 ↗

    L1SR_OBSCited in: Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  193. [193]

    Rickels MR, Robertson RP. “Pancreatic Islet Transplantation in Humans: Recent Progress and Future Directions.” Endocrine reviews (2019). PMID: 30541144 ↗

    L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  194. [194]

    Ogolo D, Achebe D, Ani F et al.. “The impact of timing, dosage, and duration of high-dose methylprednisolone on neurological recovery and complications in acute spinal cord injury: A systematic review and meta-analysis of randomized controlled trials.” The journal of spinal cord medicine (2026). PMID: 42240612 ↗

    L1SR_MA_RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  195. [195]

    Wilson LM, Herzig SJ, Marcantonio ER et al.. “Management of Diabetes and Hyperglycemia in the Hospital: A Systematic Review of Clinical Practice Guidelines.” Diabetes care (2025). PMID: 40117466 ↗

    L1GUIDELINECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  196. [196]

    Craig CM, Lawler HM, Lee CJE et al.. “PREVENT: A Randomized, Placebo-controlled Crossover Trial of Avexitide for Treatment of Postbariatric Hypoglycemia.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33616643 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  197. [197]

    Lingvay I, Bache JK, Desouza CV et al.. “Efficacy and Hypoglycemia Profile of Once-weekly Insulin Icodec vs Once-daily Comparators Across Demographic Subgroups.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40102962 ↗

    L2RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  198. [198]

    Celli A, Barnouin Y, Jiang B et al.. “Lifestyle Intervention Strategy to Treat Diabetes in Older Adults: A Randomized Controlled Trial.” Diabetes care (2022). PMID: 35880801 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  199. [199]

    Park J, Ntelis S, Yunasan E et al.. “Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37561012 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  200. [200]

    Vega-Beyhart A, Biagetti B, Marazuela M et al.. “Efficacy and Safety of Pasireotide in Insulinoma-Associated Hypoglycemia.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40165498 ↗

    L2SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  201. [201]

    McMurray JJV, Solomon SD, Inzucchi SE et al.. “Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.” The New England journal of medicine (2019). PMID: 31535829 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  202. [202]

    Kittah NE, Vella A. “MANAGEMENT OF ENDOCRINE DISEASE: Pathogenesis and management of hypoglycemia.” European journal of endocrinology (2017). PMID: 28381450 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  203. [203]

    Xie L, Lu W, Yu J et al.. “Regulation of insulin expression and release in gene and cell therapy of insulin-deficient diabetes.” European journal of endocrinology (2025). PMID: 41250859 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  204. [204]

    Abrahamsson N, Edén Engström B, Sundbom M et al.. “Hypoglycemia in everyday life after gastric bypass and duodenal switch.” European journal of endocrinology (2015). PMID: 25899582 ↗

    L3OTHERCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  205. [205]

    Raptis D, Chiotis S, Papamichalis T et al.. “Efficacy and safety of once-weekly basal insulin analogs versus daily basal insulin analogs in adults with type 2 diabetes: a systematic review and meta-analysis.” Current diabetes reports (2026). PMID: 42277362 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  206. [206]

    Gordillo-Rosas L, Cajachagua-Pucuhuaranga CL, Cruz-Venegas JS et al.. “Automated insulin delivery in type 2 diabetes: a meta-analysis of randomized trials protocol.” Systematic reviews (2026). PMID: 42265738 ↗

    L5SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  207. [207]

    Sirimaturos M, Honarmand K, Long MT et al.. “Comparison of Intensive Versus Conventional Glycemic Control Targets: An Updated Systematic Review and Meta-Analysis of the 2024 Society of Critical Care Medicine Guidelines on Glycemic Control for Critically Ill Adults.” Critical care medicine (2026). PMID: 42262517 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  208. [208]

    Rosenstock J, Juneja R, Beals JM et al.. “The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa.” Endocrine reviews (2024). PMID: 38224978 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  209. [209]

    Galindo RJ, Beck RW, Scioscia MF et al.. “Glycemic Monitoring and Management in Advanced Chronic Kidney Disease.” Endocrine reviews (2020). PMID: 32455432 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  210. [210]

    Stanley S, Moheet A, Seaquist ER. “Central Mechanisms of Glucose Sensing and Counterregulation in Defense of Hypoglycemia.” Endocrine reviews (2019). PMID: 30689785 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  211. [211]

    Narula N, Dhillon A, Zhang D et al.. “Enteral nutritional therapy for induction of remission in Crohn's disease.” The Cochrane database of systematic reviews (2018). PMID: 29607496 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention
  212. [212]

    Fan L, Xu J, Wang T et al.. “Sulfonylurea drugs for people with severe hemispheric ischemic stroke.” The Cochrane database of systematic reviews (2025). PMID: 40066941 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  213. [213]

    Galderisi A, Bruschettini M, Russo C et al.. “Continuous glucose monitoring for the prevention of morbidity and mortality in preterm infants.” The Cochrane database of systematic reviews (2020). PMID: 33348448 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention
  214. [214]

    Ozek E, Soll R, Schimmel MS. “Partial exchange transfusion to prevent neurodevelopmental disability in infants with polycythemia.” The Cochrane database of systematic reviews (2010). PMID: 20091569 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  215. [215]

    Ma X, Mo Z, Chen Y et al.. “Clinical Trial for Safety of Porcine Islet Xenotransplantation From PERV-C Free DPF Donor Piglets in Patients With Type 1 Diabetes.” Xenotransplantation (2026). PMID: 42305014 ↗

    L2TRIAL_NONRANDOMCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  216. [216]

    Borooghani H, Arabi M, Kazemi Jahromi M. “Efficacy and Safety of Oral Antidiabetic Drugs in People with Diabetes and Chronic Kidney Disease: A Systematic Review.” Iranian journal of kidney diseases (2025). PMID: 42234904 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  217. [217]

    D'Anna R, Scilipoti A, Giordano D et al.. “myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study.” Diabetes care (2013). PMID: 23340885 ↗

    L1RCTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  218. [218]

    David O, Barash G, Agur R et al.. “Multiple Endocrine Deficiencies are Common in Hypoparathyroidism-Retardation-Dysmorphism Syndrome.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33150438 ↗

    L4TRIAL_NONRANDOMCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  219. [219]

    White WB, Cannon CP, Heller SR et al.. “Alogliptin after acute coronary syndrome in patients with type 2 diabetes.” The New England journal of medicine (2013). PMID: 23992602 ↗

    L1RCTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  220. [220]

    Calder GL, Ward GM, Sachithanandan N et al.. “Insulin Autoimmune Syndrome: A Case of Clopidogrel-induced Autoimmune Hypoglycemia.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32182368 ↗

    L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  221. [221]

    Liu Y, Ping F, Yu J et al.. “Hypoglycemia Caused by Exogenous Insulin Antibody Syndrome: A Large Single-Center Case Series From China.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36219196 ↗

    L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention
  222. [222]

    Arya VB, Flanagan SE, Schober E et al.. “Activating AKT2 mutation: hypoinsulinemic hypoketotic hypoglycemia.” The Journal of clinical endocrinology and metabolism (2013). PMID: 24285683 ↗

    L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  223. [223]

    Myngheer N, Allegaert K, Hattersley A et al.. “Fetal macrosomia and neonatal hyperinsulinemic hypoglycemia associated with transplacental transfer of sulfonylurea in a mother with KCNJ11-related neonatal diabetes.” Diabetes care (2014). PMID: 25231897 ↗

    L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  224. [224]

    Rohayem J, Ehlers C, Wiedemann B et al.. “Diabetes and neurodegeneration in Wolfram syndrome: a multicenter study of phenotype and genotype.” Diabetes care (2011). PMID: 21602428 ↗

    L3OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  225. [225]

    Gupta K, Rajagopal R, King F et al.. “Complications of Antenatal Corticosteroids in Infants Born by Early Term Scheduled Cesarean Section.” Diabetes care (2020). PMID: 31974101 ↗

    L3OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  226. [226]

    Dagogo-Jack S. “Philip E. Cryer, MD: Seminal Contributions to the Understanding of Hypoglycemia and Glucose Counterregulation and the Discovery of HAAF (Cryer Syndrome).” Diabetes care (2015). PMID: 26604275 ↗

    L5OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  227. [227]

    Al Mutair AN, Brusgaard K, Bin-Abbas B et al.. “Heterogeneity in phenotype of usher-congenital hyperinsulinism syndrome: hearing loss, retinitis pigmentosa, and hyperinsulinemic hypoglycemia ranging from severe to mild with conversion to diabetes.” Diabetes care (2012). PMID: 23150283 ↗

    L4OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  228. [228]

    Li W, Wang T, Zhang J. “Antenatal corticosteroid administration-to-delivery intervals and neonatal outcomes in late preterm labor: a historical cohort study.” BMC pregnancy and childbirth (2026). PMID: 41872805 ↗

    L3COHORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  229. [229]

    Tang H, Chen Z, Wang S et al.. “Predictive value of three insulin resistance surrogate indices for symptomatic hypoglycemia risk in hospitalized patients with type 2 diabetes: a retrospective cohort study.” BMC endocrine disorders (2026). PMID: 41851856 ↗

    L3COHORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  230. [230]

    Chen Y, Song H, Yang M. “Association between glycemic variability and composite adverse neonatal outcomes in patients with gestational diabetes mellitus: a retrospective study.” The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians (2026). PMID: 42108378 ↗

    L3COHORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  231. [231]

    Shalimova A, Graff B, Gąsecki D et al.. “Cognitive Dysfunction in Type 1 Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30657922 ↗

    L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae
  232. [232]

    Bernard V, Lombard-Bohas C, Taquet MC et al.. “Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia.” European journal of endocrinology (2013). PMID: 23392213 ↗

    L4OTHERCited in: Complications and Long-term Sequelae
  233. [233]

    Hadjadj S, Ragot S, Durocher L et al.. “Impact of high intensity physical activity compared to routine counseling on renal function decline in patients with type 2 diabetes at high risk for kidney disease - the ACTIDIANE randomized controlled trial.” Diabetes & metabolism (2026). PMID: 42177980 ↗

    L1RCTCited in: Complications and Long-term Sequelae
  234. [234]

    Lal RA, Ekhlaspour L, Hood K et al.. “Realizing a Closed-Loop (Artificial Pancreas) System for the Treatment of Type 1 Diabetes.” Endocrine reviews (2019). PMID: 31276160 ↗

    L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae
  235. [235]

    Kuo CH, Lin MW, Chen SC et al.. “The Effect of Midpregnancy Screening for Gestational Diabetes Mellitus on Pregnancy Outcomes: The TESGO Randomized Controlled Trial.” Diabetes care (2026). PMID: 40986699 ↗

    L1RCTCited in: Prognosis, Natural History, Special Populations and Prevention
  236. [236]

    Buschur EO, Polsky S. “Type 1 Diabetes: Management in Women From Preconception to Postpartum.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33331893 ↗

    L5SR_OBSCited in: Prognosis, Natural History, Special Populations and Prevention
  237. [237]

    Gaudieri PA, Chen R, Greer TF et al.. “Cognitive function in children with type 1 diabetes: a meta-analysis.” Diabetes care (2008). PMID: 18753668 ↗

    L1SR_OBSCited in: Prognosis, Natural History, Special Populations and Prevention
  238. [238]

    Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J et al.. “A randomized, controlled trial of oral propranolol in infantile hemangioma.” The New England journal of medicine (2015). PMID: 25693013 ↗

    L1RCTCited in: Prognosis, Natural History, Special Populations and Prevention
  239. [239]

    Beardsall K, Vanhaesebrouck S, Ogilvy-Stuart AL et al.. “Early insulin therapy in very-low-birth-weight infants.” The New England journal of medicine (2008). PMID: 18971490 ↗

    L1RCTCited in: Prognosis, Natural History, Special Populations and Prevention
  240. [240]

    Brunkhorst FM, Engel C, Bloos F et al.. “Intensive insulin therapy and pentastarch resuscitation in severe sepsis.” The New England journal of medicine (2008). PMID: 18184958 ↗

    L1RCTCited in: Prognosis, Natural History, Special Populations and Prevention
  241. [241]

    Macrae D, Grieve R, Allen E et al.. “A randomized trial of hyperglycemic control in pediatric intensive care.” The New England journal of medicine (2014). PMID: 24401049 ↗

    L1RCTCited in: Prognosis, Natural History, Special Populations and Prevention
  242. [242]

    Stewart ZA, Wilinska ME, Hartnell S et al.. “Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes.” The New England journal of medicine (2016). PMID: 27532830 ↗

    L1RCTCited in: Prognosis, Natural History, Special Populations and Prevention
  243. [243]

    Le Quan Sang KH, Arnoux JB, Mamoune A et al.. “Successful treatment of congenital hyperinsulinism with long-acting release octreotide.” European journal of endocrinology (2011). PMID: 22048969 ↗

    L4TRIAL_NONRANDOMCited in: Prognosis, Natural History, Special Populations and Prevention
  244. [244]

    Cox DJ, Gonder-Frederick L, Ritterband L et al.. “Prediction of severe hypoglycemia.” Diabetes care (2007). PMID: 17363757 ↗

    L2OTHERCited in: Prognosis, Natural History, Special Populations and Prevention
  245. [245]

    Yland JJ, Huybrechts KF, Wesselink AK et al.. “Perinatal Outcomes Associated With Metformin Use During Pregnancy in Women With Pregestational Type 2 Diabetes Mellitus.” Diabetes care (2024). PMID: 39042587 ↗

    L2OTHERCited in: Prognosis, Natural History, Special Populations and Prevention
  246. [246]

    McGrath RT, Glastras SJ, Hocking SL et al.. “Large-for-Gestational-Age Neonates in Type 1 Diabetes and Pregnancy: Contribution of Factors Beyond Hyperglycemia.” Diabetes care (2018). PMID: 30030258 ↗

    L5REVIEW_NARRATIVECited in: Prognosis, Natural History, Special Populations and Prevention
  247. [247]

    Immanuel J, Simmons D. “A Perspective on the Accuracy of Blood Glucose Meters During Pregnancy.” Diabetes care (2018). PMID: 30237233 ↗

    L5REVIEW_NARRATIVECited in: Prognosis, Natural History, Special Populations and Prevention
  248. [248]

    Hauffa BP, Lehmann N, Bettendorf M et al.. “Central laboratory reassessment of IGF-I, IGF-binding protein-3, and GH serum concentrations measured at local treatment centers in growth-impaired children: implications for the agreement between outpatient screening and the results of somatotropic axis functional testing.” European journal of endocrinology (2007). PMID: 17984239 ↗

    L4OTHERCited in: Prognosis, Natural History, Special Populations and Prevention
  249. [249]

    Moser O, Becker U, van den Boom L et al.. “[Automated insulin delivery (AID) systems, physical activity and sports in type 1 diabetes mellitus: joint guidelines of the DDG and ÖDG].” Wiener klinische Wochenschrift (2026). PMID: 42162485 ↗

    L1GUIDELINECited in: Prognosis, Natural History, Special Populations and Prevention
  250. [250]

    Xiong Y, Huang M, Li H et al.. “Predictive Models for Hypoglycemia Risk in Haemodialysis Patients With Diabetic Kidney Disease: Systematic Review and Meta-Analysis.” Journal of clinical nursing (2026). PMID: 42246063 ↗

    L1SR_OBSCited in: Prognosis, Natural History, Special Populations and Prevention
  251. [251]

    Poyatos-León R, Martínez-Vizcaíno V, Sequí-Domínguez I et al.. “The effect of myo-inositol supplementation on gestational diabetes mellitus prevention: a systematic review and meta-analysis.” American journal of obstetrics and gynecology (2026). PMID: 42242341 ↗

    L1SR_OBSCited in: Prognosis, Natural History, Special Populations and Prevention
  252. [252]

    Domínguez-Navarro A, Lee M, Chen Y et al.. “Continuous glucose monitoring in older adults with diabetes across care settings: A systematic review.” Geriatric nursing (New York, N.Y.) (2026). PMID: 42167080 ↗

    L2SR_OBSCited in: Prognosis, Natural History, Special Populations and Prevention

Revision History

All updates applied to this page

Loading revisions…